ArticleACS chemical biology2013
Potent and selective inhibition of A-to-I RNA editing with 2'-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides.
Article in ACS chemical biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting ADAR1 in Cancer: Biology, Therapeutic Strategies, Challenges, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- ADARs: pleiotropy in function, versatility in application.Nucleic acids research · 2025Review
- Structural and functional effects of inosine modification in mRNA.RNA (New York, N.Y.) · 2024Article
- Review
- ADAR1 and its implications in cancer development and treatment.Trends in genetics : TIG · 2022Review
- A new strategy to increase RNA editing at the Q/R site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2.Journal of neuroscience methods · 2021Article
- Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- ADARs, RNA editing and more in hematological malignancies.Leukemia · 2021Review
- To protect and modify double-stranded RNA - the critical roles of ADARs in development, immunity and oncogenesis.Critical reviews in biochemistry and molecular biology · 2021Review
- RNA editing in the forefront of epitranscriptomics and human health.Journal of translational medicine · 2019Review
- The Role of RNA Editing in Cancer Development and Metabolic Disorders.Frontiers in endocrinology · 2018Review
- RNA editing-dependent epitranscriptome diversity in cancer stem cells.Nature reviews. Cancer · 2017Review
- ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.Gastroenterology · 2016Article
- Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.The Journal of clinical investigation · 2014Article
- Functional Impact of RNA editing and ADARs on regulation of gene expression: perspectives from deep sequencing studies.Cell & bioscience · 2014Review
- Deciphering the functions and regulation of brain-enriched A-to-I RNA editing.Nature neuroscience · 2013Review
- Reciprocal regulation of A-to-I RNA editing and the vertebrate nervous system.Frontiers in neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
ADARs (adenosine deaminases acting on RNA) are RNA editing enzymes that bind double helical RNAs and deaminate select adenosines (A). The product inosine (I) is read during translation as guanosine (G), so such changes can alter codon meaning. ADAR-catalyzed A to I changes occur in coding sequences for several proteins of importance to the nervous system. However, these sites constitute only a very small fraction of known A to I sites in the human transcriptome, and the significance of editing at the vast majority sites is unknown at this time. Site-selective inhibitors of RNA editing are needed to advance our understanding of the function of editing at specific sites. Here we show that 2'-O-methyl/locked nucleic acid (LNA) mixmer antisense oligonucleotides are potent and selective inhibitors of RNA editing on two different target RNAs. These reagents are capable of binding with high affinity to RNA editing substrates and remodeling the secondary structure by a strand-invasion mechanism. The potency observed here for 2'-O-methyl/LNA mixmers suggests this backbone structure is superior to the morpholino backbone structure for inhibition of RNA editing. Finally, we demonstrate antisense inhibition of editing of the mRNA for the DNA repair glycosylase NEIL1 in cultured human cells, providing a new approach to exploring the link between RNA editing and the cellular response to oxidative DNA damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.